Intravitreal Triamcinolone with Transpupillary Thermal Therapy (TTT) for Subfoveal Choroidal Neovascularization in Age Related Macular Degeneration
ISRCTN | ISRCTN74123635 |
---|---|
DOI | https://doi.org/10.1186/ISRCTN74123635 |
Secondary identifying numbers | N/A |
- Submission date
- 09/05/2005
- Registration date
- 16/05/2005
- Last edited
- 18/02/2008
- Recruitment status
- No longer recruiting
- Overall study status
- Completed
- Condition category
- Eye Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Plain English summary of protocol
Not provided at time of registration
Contact information
Dr Ricardo Agurto-Rivera
Scientific
Scientific
Exequiel Fernández nº 920
Casa F
Ñuñoa
Santiago
Chile
Phone | +56 8 5021968 |
---|---|
ricardo_agurto@yahoo.com |
Study information
Study design | Randomised controlled trial |
---|---|
Primary study design | Interventional |
Secondary study design | Randomised controlled trial |
Study setting(s) | Hospital |
Study type | Treatment |
Scientific title | |
Study objectives | TTT plus intravitreous triamcinolone are effective treatment for choroidal neovascularization and are better than TTT alone. |
Ethics approval(s) | Not provided at time of registration |
Health condition(s) or problem(s) studied | Age-Related Macular Degeneration (ARMD) not available for current therapies |
Intervention | Complete ophthalmologic examination, treatment with TTT alone compared with treatment with TTT plus intravitreous Triamcinolone. Ophthalmologic control to verify closure of CNV or re-treatment. |
Intervention type | Drug |
Pharmaceutical study type(s) | |
Phase | Not Specified |
Drug / device / biological / vaccine name(s) | Triamcinolone |
Primary outcome measure | Preservation of visual acuity |
Secondary outcome measures | Closure of CNV, OCT characteristics |
Overall study start date | 01/02/2004 |
Completion date | 28/02/2006 |
Eligibility
Participant type(s) | Patient |
---|---|
Age group | Not Specified |
Sex | Not Specified |
Target number of participants | 200 |
Key inclusion criteria | Patients with severe ARMD (choroidal neovascularization [CNV]) that could not be treated with photodynamic therapy (PDT) because of bad prognosis or economical reasons. |
Key exclusion criteria | 1. Any patient that has indication for PDT and has the economical means to get this therapy 2. Media opacity 3. Previous treatment for CNV |
Date of first enrolment | 01/02/2004 |
Date of final enrolment | 28/02/2006 |
Locations
Countries of recruitment
- Chile
- Mexico
Study participating centre
Exequiel Fernández nº 920
Santiago
Chile
Chile
Sponsor information
Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)
Not defined
Not defined
Vicente García Torres Nº 46
Barrio San Lucas
Del Coyoacán
Mexico City
04030
Mexico
Phone | +52 10841400 |
---|---|
retinamex@yahoo.com | |
https://ror.org/03sgfhr82 |
Funders
Funder type
Charity
Association to Avoid Blindness (Asociación Para Evitar La Ceguera) (APEC) (Mexico)
No information available
Results and Publications
Intention to publish date | |
---|---|
Individual participant data (IPD) Intention to share | No |
IPD sharing plan summary | Not provided at time of registration |
Publication and dissemination plan | Not provided at time of registration |
IPD sharing plan |
Study outputs
Output type | Details | Date created | Date added | Peer reviewed? | Patient-facing? |
---|---|---|---|---|---|
Results article | results | 25/11/2005 | Yes | No |